Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04732468 · ClinicalTrials.gov registry record · Phase 1
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04732468 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 28 participants.
The verdict
NCT04732468, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) and to select an optimal combination dose for future studies.
Interventions
- BIOLOGICAL hAd5-S-Fusion+N-ETSD (Suspension for injection)
- DRUG hAd5-SFusion+ N-ETSD (Oral capsule)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04732468
The ClinicalTrials.gov registry entry for NCT04732468 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hAd5-S-Fusion+N-ETSD (Suspension for injection) is the first listed.
NCT04732468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04732468 about?
NCT04732468 is a clinical study titled "COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA". This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) and to select an optimal combination dos...
What is the current status of trial NCT04732468?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-02-24. Estimated completion is 2023-01-09.
What interventions are being tested in trial NCT04732468?
The interventions under investigation include: hAd5-S-Fusion+N-ETSD (Suspension for injection) (BIOLOGICAL), hAd5-SFusion+ N-ETSD (Oral capsule) (DRUG).
Who is sponsoring clinical trial NCT04732468?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.